<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21777">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01990612</url>
  </required_header>
  <id_info>
    <org_study_id>HD36801-ARRIVE</org_study_id>
    <nct_id>NCT01990612</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Induction Versus Expectant Management</brief_title>
  <acronym>ARRIVE</acronym>
  <official_title>Induction in Nulliparous Women at 39 Weeks to Prevent Adverse Outcomes: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Among nulliparous women with singleton uncomplicated term pregnancies, elective induction of
      labor at 39 weeks, compared with expectant management, reduces the risk of severe neonatal
      morbidity and perinatal mortality.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>composite of severe neonatal morbidity and perinatal mortality</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The composite includes any one of the following:
Antepartum, intrapartum, or neonatal death
Intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula (HFNC) for ventilation or cardiorespiratory support within first 72 hours
Apgar â‰¤ 3 at 5 minutes
Neonatal encephalopathy as defined by Shankaran et al.48
Seizures
Sepsis.  The diagnosis of sepsis will require the presence of a clinically ill infant in whom systemic infection is suspected with a positive blood, CSF, or catheterized/suprapubic urine culture; or, in the absence of positive cultures, clinical evidence of cardiovascular collapse or an unequivocal X-ray confirming infection.
Pneumonia confirmed by X-ray or positive blood culture.
Meconium aspiration syndrome
Birth trauma (bone fractures, brachial plexus palsy, other neurologic injury, retinal hemorrhage facial nerve injury)
Intracranial hemorrhage or subgaleal hemorrhage
Hypotension requiring pressor support</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cesarean delivery and indication</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incisional extensions at cesarean section, including J shape or T shape; or cervical traumas</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative vaginal delivery and indication</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chorioamnionitis, defined as a clinical diagnosis before delivery</measure>
    <time_frame>before delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Third or fourth degree perineal laceration</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal death</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to intensive care unit (ICU)</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preeclampsia/gestational hypertension</measure>
    <time_frame>before delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postpartum hemorrhage</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
    <description>defined as any of the following:
Clinical diagnosis of endometritis
Wound reopened for hematoma, seroma, infection or other reasons
Cellulitis requiring antibiotics
Pneumonia
Pyelonephritis
Bacteremia unknown source
Septic pelvic thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal venous thromboembolism (deep venous thrombosis or pulmonary embolism)</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight, macrosomia &gt; 4500 g, large for gestational age (LGA) defined as &gt; 90th percentile weight for gestational age, assessed specifically by sex and race of the infant based on United States birth certificate data</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of respiratory support including ventilator, CPAP, high-flow nasal cannula (HFNC)</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small for gestational age defined as &lt; 5th  and &lt; 10th percentile weight for gestational age, assessed specifically by sex and race of the infant based on United States birth certificate data</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cephalohematoma</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shoulder dystocia</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion of blood products or blood</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperbilirubinemia requiring phototherapy or exchange transfusion</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia (glucose &lt; 40 mg%) requiring IV therapy</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to neonatal intensive care unit (NICU) or intermediate care unit</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinic visits post randomization to admission for delivery</measure>
    <time_frame>randomization until delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ER/urgent care/triage visits post randomization to delivery</measure>
    <time_frame>randomization until delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-stress tests, biophysical profiles (BPPs), modified BPPs, ultrasounds done other than BPP, Doppler, contraction stress tests</measure>
    <time_frame>randomization until delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidural use</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine pressure catheter (IUPC) or fetal scalp electrode placement</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of induction and ripening agents, maximum dose of oxytocin</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antepartum hospital admission</measure>
    <time_frame>antepartum</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hours on the labor and delivery unit</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal postpartum length of hospital stay</measure>
    <time_frame>after delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal length of hospital stay</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of neonatal intensive care unit or intermediate care stay</measure>
    <time_frame>delivery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post discharge resource utilization including inpatient and outpatient visits for mother or baby</measure>
    <time_frame>discharge to 6 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Labor and Delivery</condition>
  <arm_group>
    <arm_group_label>Expectnant Management</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Expectant management (unless a medical indication arises) until at least 40 weeks 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elective Induction of Labor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Elective induction of labor between 39 weeks 0 days and 39 weeks 4 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Elective Induction of Labor</intervention_name>
    <description>Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days.  Those with an unfavorable cervix (modified Bishop score &lt; 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.</description>
    <arm_group_label>Elective Induction of Labor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Nulliparous - no previous pregnancy beyond 20 weeks

          2. Singleton gestation.  Twin gestation reduced to singleton, either spontaneously or
             therapeutically, is not eligible unless the reduction occurred before 14 weeks
             project gestational age.

          3. Gestational age at randomization between 38 weeks 0 days and 38 weeks 6 days
             inclusive based on clinical information and evaluation of the earliest ultrasound.

             -

             Exclusion Criteria:

        1. Project gestational age at date of first ultrasound is &gt; 20 weeks 6 days 2. Plan for
        induction of labor prior to 40 weeks 5 days 3. Plan for cesarean delivery or
        contraindication to labor 4. Signs of labor (regular painful contractions with cervical
        change) 5. Fetal demise or known major fetal anomaly 6. Heparin or low-molecular weight
        heparin during the current pregnancy 7. Placenta previa, accreta, vasa previa 8. Active
        vaginal bleeding greater than bloody show 9. Ruptured membranes 10. Cerclage in current
        pregnancy 11. Known oligohydramnios, defined as AFI &lt; 5 or MVP &lt; 2 12. Fetal growth
        restriction, defined as EFW &lt; 10th percentile 13. Known HIV positivity because of modified
        delivery plan 14. Major maternal medical illness associated with increased risk for
        adverse pregnancy outcome  (for example, any diabetes mellitus, lupus, any hypertensive
        disorder, cardiac disease, renal insufficiency) 15. Refusal of blood products 16.
        Participation in another interventional study that influences management of labor at
        delivery or perinatal morbidity or mortality 17. Delivery planned elsewhere at a
        non-Network site

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uma Reddy, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Thom, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Grobman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uma Reddy, MD, MPH</last_name>
    <phone>301-496-1074</phone>
    <email>uma.reddy@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Harris, BSN</last_name>
      <phone>205-996-6262</phone>
      <email>stacylharris@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alan TN Tita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5317</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Willson, RN, BSN</last_name>
      <phone>650-724-6372</phone>
      <email>cwillson@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Yasser El-Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Hale, RN BSN</last_name>
      <phone>303-724-6685</phone>
      <email>kathy.a.hale@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Gibbs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University-Prentice Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Mallett</last_name>
      <email>g-mallett@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>William Grobman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University-St. Luke's Hospital</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Bousleiman, MSN</last_name>
      <phone>212-305-4348</phone>
      <email>sb1080@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ronald J Wapner, MD</last_name>
      <phone>212-305-6293</phone>
      <email>RW2191@columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Wapner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina - Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelly Clark, RN</last_name>
      <phone>919-350-6117</phone>
      <email>kelly_clark@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>John M Thorp, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tammy S Bishop, RNC MSN</last_name>
      <phone>919-668-7475</phone>
      <email>sincl008@mc.duke.edu</email>
    </contact>
    <investigator>
      <last_name>Geeta K Swamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wendy Dalton, RNC</last_name>
      <phone>216-778-7533</phone>
      <email>wdalton@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Edward Chien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francee Johnson, RN</last_name>
      <phone>614-293-5632</phone>
      <email>johnson.126@osu.edu</email>
    </contact>
    <investigator>
      <last_name>Jay D Iams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Allard, RNC</last_name>
      <phone>401-274-1122</phone>
      <email>dallard@wihri.org</email>
    </contact>
    <investigator>
      <last_name>Dwight J Rouse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of OB/GYN, Southwestern Medical Center, University of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-9032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Moseley, RN</last_name>
      <phone>214-590-1835</phone>
      <email>lisa.moseley@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth J Leveno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Moseley, RN</last_name>
      <email>lisa.moseley@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <phone>214-648-2591</phone>
    </contact_backup>
    <investigator>
      <last_name>Brian Casey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Salazar, MSN</last_name>
      <phone>409-772-0312</phone>
      <email>assalaza@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>George R Saade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felecia Ortiz, RN BSN</last_name>
      <phone>713-500-6467</phone>
      <email>Felecia.Ortiz@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Baha Sibai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Hill, RN</last_name>
      <phone>801-585-7645</phone>
      <email>Kim.Hill@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Michael W Varner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>November 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
